These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 26745973)

  • 21. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
    Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
    Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
    Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims.
    Weycker D; Hanau A; Lonshteyn A; Bowers C; Bensink M; Garawin T; Chandler D
    Curr Med Res Opin; 2018 Sep; 34(9):1705-1711. PubMed ID: 29962268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.
    Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
    Curr Med Res Opin; 2017 Dec; 33(12):2107-2113. PubMed ID: 28958157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
    Weycker D; Li X; Figueredo J; Barron R; Tzivelekis S; Hagiwara M
    Support Care Cancer; 2016 May; 24(5):2309-2316. PubMed ID: 26607482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
    Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
    Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
    Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
    J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
    Mahtani RL; Belani R; Crawford J; Dale D; DeCosta L; Gawade PL; Huynh C; Lawrence T; Lewis S; MacLaughlin WW; Narang M; Rifkin R
    Support Care Cancer; 2022 Jul; 30(7):6135-6144. PubMed ID: 35426046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
    Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
    Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.
    Rapoport BL; Aapro M; Paesmans M; van Eeden R; Smit T; Krendyukov A; Klastersky J
    BMC Cancer; 2018 Sep; 18(1):917. PubMed ID: 30249215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
    Fust K; Li X; Maschio M; Barron R; Weinstein MC; Parthan A; Walli-Attaei M; Chandler DB; Lyman GH
    Gynecol Oncol; 2014 Jun; 133(3):446-53. PubMed ID: 24657302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study.
    Jurczak W; Kalinka-Warzocha E; Chmielowska E; Duchnowska R; Wojciechowska-Lampka E; Wieruszewska K
    Contemp Oncol (Pozn); 2015; 19(3):214-9. PubMed ID: 26557762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
    Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
    Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
    Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
    Rifkin RM; Crawford J; Mahtani RL; Dale DC; Narang M; MacLaughlin WW; Huynh C; Gawade PL; Lewis S; DeCosta L; Lawrence T; Belani R
    Support Care Cancer; 2022 Oct; 30(10):7913-7922. PubMed ID: 35732748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey.
    Link H; Kerkmann M; Holtmann L; Ortner P;
    Support Care Cancer; 2019 Apr; 27(4):1459-1469. PubMed ID: 30374765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
    Almenar D; Mayans J; Juan O; Bueno JM; Lopez JI; Frau A; Guinot M; Cerezuela P; Buscalla EG; Gasquet JA; Sanchez J
    Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.